1
|
Comparative efficacy of antihypertensive drugs in dogs: a systematic review. Top Companion Anim Med 2022; 50:100674. [DOI: 10.1016/j.tcam.2022.100674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 05/10/2022] [Accepted: 05/17/2022] [Indexed: 11/20/2022]
|
2
|
Ward JL, Chou YY, Yuan L, Dorman KS, Mochel JP. Retrospective evaluation of a dose-dependent effect of angiotensin-converting enzyme inhibitors on long-term outcome in dogs with cardiac disease. J Vet Intern Med 2021; 35:2102-2111. [PMID: 34387901 PMCID: PMC8478030 DOI: 10.1111/jvim.16236] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 07/22/2021] [Accepted: 07/22/2021] [Indexed: 12/02/2022] Open
Abstract
Background Angiotensin‐converting enzyme inhibitors (ACEIs) are commonly prescribed in dogs, but the ideal dosage is unknown. Hypothesis/Objectives In dogs with cardiac disease, a dose‐response relationship exists for ACEIs with respect to long‐term outcome. Animals One hundred forty‐four dogs with cardiac disease, 63 with current or prior congestive heart failure. Methods Retrospective medical record review. Cox proportional hazards models were used to determine variables associated with 2‐year survival or survival from first‐onset congestive heart failure (CHF). Results Median initial ACEI dosage was 0.84 (interquartile range [IQR], 0.56‐0.98) mg/kg/day, and 108/144 (75%) of dogs received q12h dosing. No clinically relevant changes in renal function test results, serum electrolyte concentrations, or blood pressure occurred between initial prescription of ACEI and first reevaluation (median, 14 days later). In univariable analysis, higher ACEI dose was associated with increased survival from first‐onset CHF (P = .005), and within the subgroup of dogs in CHF at the time of ACEI prescription, higher ACEI dose was associated with improved survival at 2 years (P = .04). In multivariable analysis, q12h dose frequency of ACEI (hazard ratio [HR], 0.30; 95% CI, 0.10‐0.88; P = .03) and higher serum potassium concentration at visit 1 (HR, 0.39; 95% CI, 0.16‐0.97; P = .04) were predictive of 2‐year survival. The ACEIs were well‐tolerated, with only 8/144 (5.6%) dogs having ACEI dose decreased or discontinued because of adverse effects. Conclusions and Clinical Importance Twice daily dose frequency might optimize the cardioprotective benefit of ACEIs.
Collapse
Affiliation(s)
- Jessica L Ward
- Department of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa, USA
| | - Yen-Yu Chou
- Department of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa, USA
| | - Lingnan Yuan
- Department of Statistics, Iowa State University, Ames, Iowa, USA.,Department of Biomedical Sciences, SMART Pharmacology, Iowa State University, Ames, Iowa, USA
| | - Karin S Dorman
- Department of Statistics, Iowa State University, Ames, Iowa, USA.,Department of Genetics, Development and Cell Biology, Iowa State University, Ames, Iowa, USA
| | - Jonathan P Mochel
- Department of Biomedical Sciences, SMART Pharmacology, Iowa State University, Ames, Iowa, USA
| |
Collapse
|
3
|
King J, Font A, Rousselot J, Ash R, Bonfanti U, Brovida C, Crowe I, Lanore D, Pechereau D, Seewald W, Strehlau G. Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial. J Vet Intern Med 2017; 31:1113-1122. [PMID: 28669137 PMCID: PMC5508345 DOI: 10.1111/jvim.14726] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 02/16/2017] [Accepted: 04/06/2017] [Indexed: 01/10/2023] Open
Abstract
BACKGROUND Chronic kidney disease (CKD) is an important cause of morbidity and mortality in dogs. OBJECTIVE To evaluate the efficacy in prolonging survival and safety of benazepril administration to dogs with CKD. ANIMALS Forty-nine client-owned dogs with CKD. METHODS Dogs were randomized to benazepril (0.25 to <0.5 mg/kg) or placebo once daily for up to 2 years in a prospective, multicenter, blinded clinical trial. The primary endpoint variable was the renal survival time, defined as the time from inclusion in the study to the treatment failure endpoint of death or euthanasia or need for administration of parenteral fluids related to renal failure. RESULTS No benefit of benazepril versus placebo was detected for renal survival time in all dogs; median (95% confidence interval (CI)) survival times were 305 (53-575) days in the benazepril group and 287 (152-not available) in the placebo group (P = .53). Renal survival times were not significantly longer with benazepril compared to placebo for subgroups: hazard ratios (95% CI) were 0.50 (0.21-1.22) with P = .12 for initial urine protein-to-creatinine ratio (UPC) >0.5, and 0.38 (0.12-1.19) with P = .080 for initial UPC >0.5 plus plasma creatinine ≤440 μmol/L. Proteinuria, assessed from the UPC, was significantly (P = .0032) lower after treatment with benazepril compared to placebo. There were no significant differences between groups for clinical signs or frequencies of adverse events. CONCLUSIONS AND CLINICAL RELEVANCE Benazepril significantly reduced proteinuria in dogs with CKD. Insufficient numbers of dogs were recruited to allow conclusions on survival time.
Collapse
Affiliation(s)
- J.N. King
- Elanco Animal HealthBaselSwitzerland
| | - A. Font
- Hospitar Ars VeterinariaBarcelonaSpain
| | | | - R.A. Ash
- Grove Lodge Veterinary GroupBrightonUK
| | - U. Bonfanti
- La Vallonèa Veterinary Diagnostic LaboratoryAlessanoItaly
| | - C. Brovida
- ANUBI Ospedale per Animali da CompagniaMoncalieri/TorinoItaly
| | | | - D. Lanore
- Clinique Vétérinaire AllianceBordeauxFrance
| | | | | | | |
Collapse
|
4
|
Lavallee JO, Norsworthy GD, Huston CL, Chew DJ. Safety of Benazepril in 400 Azotemic and 110 Non-Azotemic Client-Owned Cats (2001-2012). J Am Anim Hosp Assoc 2017; 53:119-127. [PMID: 28282231 DOI: 10.5326/jaaha-ms-6577] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
This retrospective study examined cats after initiation of benazepril therapy to determine the frequency of systemic hypotension or elevations in serum creatinine and/or potassium. Medical records review identified azotemic and non-azotemic cats prescribed benazepril. Blood pressure was recorded at the first available time after initiation of therapy. No cats experienced documented systolic systemic hypotension (<90 mmHg). Serum creatinine, and potassium when available, were recorded at baseline and in time windows after initiation of treatment: 1-30 days and 31-60 days. Blood chemistry results were screened for hyperkalemia (≥6.0 mEq/L). During the first 2 mo after starting benazepril therapy, there was a low incidence (3.7%) and clinically insignificant magnitude of hyperkalemia. Serum creatinine increases of greater than 30% from baseline were noted. This change was found in 11.0% of cats during the first 30 days of therapy and in 13.7% of cats from days 31-60 after initiation of therapy. The long-term survival of the cats that had >30% increases in creatinine from baseline was not statistically different from the survival of those that did not experience these increases, which suggests this finding may not be a reason to discontinue therapy. Benazepril appeared safe in a heterogeneous population of cats.
Collapse
Affiliation(s)
- Jennifer O Lavallee
- From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.)
| | - Gary D Norsworthy
- From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.)
| | - Carla L Huston
- From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.)
| | - Dennis J Chew
- From Cat Specialist, Castle Rock, Colorado (J.O.L.); Alamo Feline Health Center, San Antonio, Texas (G.D.N.); Department of Pathobiology and Population Medicine, Mississippi State College of Veterinary Medicine, Starkville, Mississippi (C.L.H.); and Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio (D.J.C.)
| |
Collapse
|
5
|
Current Understanding of the Pathogenesis of Progressive Chronic Kidney Disease in Cats. Vet Clin North Am Small Anim Pract 2016; 46:1015-48. [PMID: 27461408 DOI: 10.1016/j.cvsm.2016.06.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
In cats with chronic kidney disease (CKD), the most common histopathologic finding is tubulointerstitial inflammation and fibrosis. However, these changes reflect a nonspecific response of the kidney to any inciting injury. The risk of developing CKD is likely to reflect the composite effects of genetic predisposition, aging, and environmental and individual factors that affect renal function over the course of a cat's life. However, there is still little information available to determine exactly which individual risk factors predispose a cat to develop CKD. Although many cats diagnosed with CKD have stable disease for years, some cats show overtly progressive disease.
Collapse
|
6
|
Effect of benazepril, robenacoxib and their combination on glomerular filtration rate in cats. BMC Vet Res 2016; 12:124. [PMID: 27338786 PMCID: PMC4917992 DOI: 10.1186/s12917-016-0734-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Accepted: 06/07/2016] [Indexed: 11/10/2022] Open
Abstract
Background Combined use of angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs may induce acute kidney injury in humans, especially when combined with diuretics. The objective of this investigation was to evaluate the effects of benazepril, robenacoxib and their combination in healthy cats. In each of two studies (study 1 followed by study 2), 32 healthy cats were randomised to one of four groups (n = 4 male and 4 female cats per group) in a parallel-group design. The groups received orally once daily for 7 days either placebo (control group), benazepril, robenacoxib or benazepril plus robenacoxib. In study 2, all groups received in addition 0.5 mg/kg furosemide twice daily by subcutaneous injection for 7 days. Results Benazepril, robenacoxib and their combination were well tolerated as evidenced from lack of clinical signs and no negative effects on body weight, feed consumption and clinical chemistry, haematology and urinalysis variables. The primary endpoint of the study was the glomerular filtration rate (GFR), which was estimated from the plasma clearance of iohexol. In the absence of furosemide, GFR was significantly higher in cats receiving the combination of benazepril plus robenacoxib compared to the other three groups, and was also significantly higher in females receiving only benazepril compared to the control. Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system, evidenced from increased plasma renin activity and plasma aldosterone concentrations. Compared to the control group in cats treated with furosemide, GFR was increased by benazepril (females only) but decreased by robenacoxib (males only). Benazepril, robenacoxib and their combination significantly inhibited the increase in plasma aldosterone induced by furosemide. Conclusions The combination of benazepril and robenacoxib was well tolerated and either increased or had a neutral effect on GFR in healthy cats without or with concomitant furosemide. The combination of benazepril and robenacoxib reduced plasma aldosterone concentrations increased by furosemide. It is recommended to test the efficacy and safety of the combined use of benazepril and robenacoxib in cats with clinical disease, notably proteinuric chronic kidney disease.
Collapse
|
7
|
Panteri A, Kukk A, Desevaux C, Seewald W, King JN. Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs. J Vet Pharmacol Ther 2016; 40:44-56. [PMID: 27302598 DOI: 10.1111/jvp.12325] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2015] [Accepted: 04/20/2016] [Indexed: 11/30/2022]
Abstract
Combined use of angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs may induce acute kidney injury, especially when combined with diuretics. The objective of this investigation was to evaluate the effect of benazepril, robenacoxib and their combination in healthy dogs. In each of two studies (studies 1 and 2), 32 beagle dogs were randomized into one of four groups in a parallel-group design. Groups received once-daily oral treatment for 7 days with placebo, benazepril, robenacoxib or benazepril plus robenacoxib. In study 2, all dogs received additionally 2 mg/kg furosemide orally twice daily. The primary endpoint was the glomerular filtration rate (GFR) estimated from the plasma clearance of iohexol. Secondary endpoints included standard clinical monitoring and, in study 2, plasma renin activity, urine volume, specific gravity and aldosterone concentration and water intake. Administration of furosemide induced diuresis, reduced GFR and activated the renin-aldosterone-angiotensin system. Benazepril and robenacoxib, administered alone or in combination, were tolerated well, did not decrease GFR with or without co-administration of furosemide and significantly reduced urinary aldosterone concentrations. No increased risk of acute kidney injury was identified with the combination of benazepril and robenacoxib in healthy dogs. Different effects might occur in dogs with heart or renal disease.
Collapse
Affiliation(s)
- A Panteri
- Preclinical, Elanco Centre de Recherche Santé Animale, St-Aubin, Switzerland
| | - A Kukk
- Preclinical, Elanco Centre de Recherche Santé Animale, St-Aubin, Switzerland
| | - C Desevaux
- Safety, Elanco Animal Health, Basel, Switzerland
| | - W Seewald
- Companion Animal Development, Elanco Animal Health, Basel, Switzerland
| | - J N King
- Companion Animal Development, Elanco Animal Health, Basel, Switzerland
| |
Collapse
|
8
|
Sparkes AH, Caney S, Chalhoub S, Elliott J, Finch N, Gajanayake I, Langston C, Lefebvre HP, White J, Quimby J. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg 2016; 18:219-39. [PMID: 26936494 PMCID: PMC11148907 DOI: 10.1177/1098612x16631234] [Citation(s) in RCA: 78] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/27/2024]
Abstract
PRACTICAL RELEVANCE Chronic kidney disease (CKD) is one of the most commonly diagnosed diseases in older cats. In most cats, CKD is also a progressive disease and can be accompanied by a wide range of clinical and clinicopathological changes. These ISFM Consensus Guidelines have been developed by an independent panel of clinicians and academics to provide practical advice on the diagnosis and management of this complex disease. CLINICAL CHALLENGES Although CKD is a common clinical problem in cats, the manifestations of disease vary between individuals. Thus there is a need for careful and repeat evaluation of cats with CKD and adjustment of therapy according to individual needs. In addition to addressing problems arising from CKD and improving quality of life (QoL) for the patient, therapy may also target slowing the underlying progression of disease and hence prolonging life. While maintaining QoL is of paramount importance in our patients, this can be challenging when multiple therapies are indicated. In some cases it is necessary to prioritise therapy, given an understanding of what is likely to most benefit the individual patient. EVIDENCE BASE In preparing these Guidelines, the Panel has carefully reviewed the existing published literature, and has also graded the quality of evidence for different interventions to help to provide practical recommendations on the therapeutic options for feline CKD. This is a field of veterinary medicine that has benefited from some excellent published clinical research and further research findings will undoubtedly modify the recommendations contained in these Guidelines in the future.
Collapse
Affiliation(s)
| | | | - Serge Chalhoub
- Faculty of Veterinary Medicine, University of Calgary, Canada
| | - Jonathan Elliott
- Department of Comparative Biomedical Sciences, Royal Veterinary College, UK
| | - Natalie Finch
- Bristol Renal, School of Clinical Sciences, University of Bristol, UK
| | | | | | - Hervé P Lefebvre
- Clinical Research Unit, National Veterinary School of Toulouse (ENVT), France
| | - Joanna White
- Small Animal Specialist Hospital, Sydney, Australia
| | - Jessica Quimby
- Department of Clinical Veterinary Sciences, Colorado State University, USA
| |
Collapse
|
9
|
Höglund K, Lequarré AS, Ljungvall I, Mc Entee K, Merveille AC, Wiberg M, Gouni V, Lundgren Willesen J, Hanås S, Wess G, Mejer Sørensen L, Tiret L, Kierczak M, Forsberg SKG, Seppälä E, Lindblad-Toh K, Lohi H, Chetboul V, Fredholm M, Häggström J. Effect of Breed on Plasma Endothelin-1 Concentration, Plasma Renin Activity, and Serum Cortisol Concentration in Healthy Dogs. J Vet Intern Med 2016; 30:566-73. [PMID: 26812988 PMCID: PMC4913606 DOI: 10.1111/jvim.13829] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2015] [Revised: 10/23/2015] [Accepted: 12/21/2015] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND There are breed differences in several blood variables in healthy dogs. OBJECTIVE Investigate breed variation in plasma endothelin-1 (ET-1) concentration, plasma renin activity, and serum cortisol concentration. ANIMALS Five-hundred and thirty-one healthy dogs of 9 breeds examined at 5 centers (2-4 breeds/center). METHODS Prospective observational study. Circulating concentrations of ET-1 and cortisol, and renin activity, were measured using commercially available assays. Absence of organ-related or systemic disease was ensured by thorough clinical investigations, including blood pressure measurement, echocardiography, ECG, blood and urine analysis. RESULTS Median ET-1 concentration was 1.29 (interquartile range [IQR], 0.97-1.82) pg/mL, median cortisol concentration 46.0 (IQR, 29.0-80.8) nmol/L, and median renin activity 0.73 (IQR, 0.48-1.10) ng/mL/h in all dogs. Overall, breed differences were found in ET-1 and cortisol concentrations, and renin activity (P < .0001 for all). Pair-wise comparisons between breeds differed in 67% of comparisons for ET-1, 22% for cortisol, and 19% for renin activity, respectively. Within centers, breed differences were found at 5/5 centers for ET-1, 4/5 centers for cortisol, and 2/5 centers for renin activity. Newfoundlands had highest median ET-1 concentration, 3 times higher than Cavalier King Charles Spaniels, Doberman Pinschers, and Dachshunds. Median renin activity was highest in Dachshunds, twice the median value in Newfoundlands and Boxers. Median cortisol concentration was highest in Finnish Lapphunds, almost 3 times higher than in Boxers. CONCLUSIONS AND CLINICAL IMPORTANCE Breed variation might be important to take into consideration when interpreting test results in clinical studies.
Collapse
Affiliation(s)
- K Höglund
- Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - A-S Lequarré
- Faculty of Veterinary Medicine, University of Liège, Liège, Belgium
| | - I Ljungvall
- Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - K Mc Entee
- Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
| | - A-C Merveille
- Faculty of Veterinary Medicine, University of Liège, Liège, Belgium
| | - M Wiberg
- Faculty of Veterinary Medicine, University of Helsinki, Helsinki, Finland
| | - V Gouni
- Ecole nationale vétérinaire d'Alfort, Université Paris-Est Créteil, Créteil, France.,Inserm, U955, Equipe 3, Créteil, France
| | - J Lundgren Willesen
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - S Hanås
- Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, Uppsala, Sweden.,Evidensia Animal Clinic, Västerås, Sweden
| | - G Wess
- Ludwig-Maximilians-Universität, Munich, Germany
| | - L Mejer Sørensen
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - L Tiret
- Ecole nationale vétérinaire d'Alfort, Université Paris-Est Créteil, Créteil, France.,Inserm, U955 IMRB, Equipe 10 BNMS, Créteil, France
| | - M Kierczak
- Faculty of Medicine, Uppsala University, Uppsala, Sweden
| | - S K G Forsberg
- Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, Uppsala, Sweden
| | - E Seppälä
- University of Helsinki and Folkhälsan Research Center, Helsinki, Finland
| | - K Lindblad-Toh
- Faculty of Medicine, Uppsala University, Uppsala, Sweden.,Broad Institute of MIT and Harvard, Cambridge, MA
| | - H Lohi
- University of Helsinki and Folkhälsan Research Center, Helsinki, Finland
| | - V Chetboul
- Ecole nationale vétérinaire d'Alfort, Université Paris-Est Créteil, Créteil, France.,Inserm, U955, Equipe 3, Créteil, France
| | - M Fredholm
- Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - J Häggström
- Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences, Uppsala, Sweden
| |
Collapse
|
10
|
Cortadellas O, Talavera J, Fernández del Palacio MJ. Evaluation of the effects of a therapeutic renal diet to control proteinuria in proteinuric non-azotemic dogs treated with benazepril. J Vet Intern Med 2013; 28:30-7. [PMID: 24372810 PMCID: PMC4895532 DOI: 10.1111/jvim.12246] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2012] [Revised: 08/06/2013] [Accepted: 09/25/2013] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Angiotensin-converting enzyme inhibitors (ACEIs) are currently used to control proteinuria in dogs with chronic kidney disease. Renal diets (RDs) have beneficial effects in the management of azotemic dogs, but its role in proteinuric non-azotemic (PNAz) dogs has been poorly documented. HYPOTHESIS Administration of a RD to PNAz dogs treated with benazepril (Be) improves proteinuria control compared with the administration of a maintenance diet (MD). ANIMALS Twenty-two PNAz (urine protein/creatinine ratio [UPC] >1) dogs. METHODS Randomized open label clinical trial design. Dogs were assigned to group-MD (5.5 g protein/100 kcal ME)/Be or to group-RD (3.7 g protein/100 kcal ME)/Be group during 60 days. Dogs with serum albumin (Alb) <2 g/dL received aspirin (1 mg/kg/12 hours). A physical examination, systolic blood pressure (SBP) measurement, complete blood count (CBC), biochemistry panel, urinalysis, and UPC were performed at day 0 (D0) and day 60 (D60). RESULTS At D0, there were no significant differences between groups in the evaluated variables. During the study, logUPC (geometric mean (95% CI) and SBP (mean±SD mmHg) significantly decreased (paired t-test, P = 0.001) in Group-RD (logUPC(D0) = 3.16[1.9-5.25]; UPC(D60) = 1.20 [0.59-2.45]; SBP(D0) = 160 ± 17.2; SBP(D60) = 151 ± 15.8), but not in Group-MD (UPC(D0) = 3.63[2.69-4.9]; UPC(D60) = 2.14 [0.76-6.17]; SBP(D0) = 158 ± 14.7; SBP(D60) = 153 ± 11.5). However, RM-ANOVA test did not confirm that changes were consequence of dietary modification. Weight and Alb concentration did not change significantly in any group. CONCLUSION AND CLINICAL RELEVANCE The administration of a RD to PNAz dogs treated with Be might help to control proteinuria and SBP compared with the administration of a MD, without inducing clinically detectable malnutrition, but more studies are warranted.
Collapse
Affiliation(s)
- O Cortadellas
- Clínica Veterinaria Germanías, Gandía-Valencia, Spain
| | | | | |
Collapse
|
11
|
Abstract
PRACTICAL RELEVANCE Chronic kidney disease (CKD) is one of the most frequently encountered disorders in cats, having increased in prevalence in recent decades. Although the underlying cause is rarely identified, the common final outcome of feline CKD is tubulointerstitial fibrosis. Knowledge of CKD pathophysiology is necessary for optimal individualised patient management, especially with regard to diagnosis and treatment of extrarenal complications. PATIENT GROUP CKD is most common in senior and geriatric cats, but should be considered in any feline patient with ureterolithiasis, hyperthyroidism, retrovirus infection, systemic hypertension, cardiovascular disease or urinary tract infection. EVIDENCE BASE Most of our knowledge of the pathogenesis of CKD is extrapolated from human nephrology and experimental animal studies. There is, therefore, a need for further studies in cats. The prevalence of clinical signs in feline CKD is well documented. Several concurrent diseases associated with CKD have also been reported in cats, especially in the geriatric population, but there is no or only limited published evidence demonstrating a cause-and-effect relationship between most of these conditions and CKD. Studies performed over the past 15 years have nevertheless allowed identification of major risk factors (proteinuria, plasma phosphate and plasma creatinine) influencing the progression of feline CKD. CLINICAL CHALLENGES Clinical signs occur in the late stages of renal disease, so populations at higher risk of CKD should be screened routinely. CKD-associated complications (systemic hypertension, secondary renal hyperparathyroidism, hypokalaemia, anaemia, metabolic acidosis) must not be overlooked as they may affect the progression of disease. Disease progression is itself unpredictable and renal function may remain stable for extended periods. Most cats with early CKD do not progress to end-stage CKD before they die. AUDIENCE General practitioners play a major role in screening feline patients at risk of development or progression of CKD.
Collapse
Affiliation(s)
- Brice S Reynolds
- Clinical Research Unit, National Veterinary School of Toulouse, 23 chemin des Capelles, 31076 Toulouse cedex 03, France
| | - Hervé P Lefebvre
- Clinical Research Unit, National Veterinary School of Toulouse, 23 chemin des Capelles, 31076 Toulouse cedex 03, France
| |
Collapse
|
12
|
Abstract
PRACTICAL RELEVANCE Treatment of feline chronic kidney disease (CKD) tends to focus on minimising the adverse effects of reduced renal function, rather than addressing an underlying cause. Despite this, and the progressive nature of CKD, treatment can improve quality of life and enable many cats to have long survival times. EVIDENCE BASE Strong evidence supports the provision of renal diets, which are protein and phosphorus restricted; compliance is improved by gradual dietary transition. Additional phosphorus restriction is achieved by the use of phosphate binding agents, although it is unknown if these yield similar survival benefits to those provided by renal diets. Interventions to control hypokalaemia and hypertension in affected cats are important to prevent serious complications. Administration of benazepril to cats with proteinuric kidney disease has been shown to significantly improve their appetite but not their survival. As CKD progresses, many cats will benefit from treatment to control clinical signs of uraemic gastroenteritis and anaemia.
Collapse
Affiliation(s)
- Rachel M Korman
- Feline Friendly Practice, Veterinary Specialist Services, Underwood 4009, Australia
| | - Joanna D White
- Institute of Veterinary, Animal and Biomedical Sciences, Massey University, New Zealand
| |
Collapse
|
13
|
Afonso T, Giguère S, Rapoport G, Berghaus L, Barton M, Coleman A. Pharmacodynamic Evaluation of 4 Angiotensin-Converting Enzyme Inhibitors in Healthy Adult Horses. J Vet Intern Med 2013; 27:1185-92. [DOI: 10.1111/jvim.12153] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2013] [Revised: 04/23/2013] [Accepted: 07/02/2013] [Indexed: 10/26/2022] Open
Affiliation(s)
- T. Afonso
- Department of Large Animal Medicine; College of Veterinary Medicine; University of Georgia; Athens GA
| | - S. Giguère
- Department of Large Animal Medicine; College of Veterinary Medicine; University of Georgia; Athens GA
| | - G. Rapoport
- Department of Small Animal Medicine and Surgery (Rapoport, Coleman); College of Veterinary Medicine; University of Georgia; Athens GA
| | - L.J. Berghaus
- Department of Large Animal Medicine; College of Veterinary Medicine; University of Georgia; Athens GA
| | - M.H. Barton
- Department of Large Animal Medicine; College of Veterinary Medicine; University of Georgia; Athens GA
| | - A.E. Coleman
- Department of Small Animal Medicine and Surgery (Rapoport, Coleman); College of Veterinary Medicine; University of Georgia; Athens GA
| |
Collapse
|
14
|
EBNER T, SCHÄNZLE G, WEBER W, SENT U, ELLIOTT J. In vitroglucuronidation of the angiotensin II receptor antagonist telmisartan in the cat: a comparison with other species. J Vet Pharmacol Ther 2012; 36:154-60. [DOI: 10.1111/j.1365-2885.2012.01398.x] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Gowan RA, Lingard AE, Johnston L, Stansen W, Brown SA, Malik R. Retrospective case-control study of the effects of long-term dosing with meloxicam on renal function in aged cats with degenerative joint disease. J Feline Med Surg 2011; 13:752-61. [PMID: 21906984 PMCID: PMC10832752 DOI: 10.1016/j.jfms.2011.06.008] [Citation(s) in RCA: 72] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/13/2011] [Indexed: 11/18/2022]
Abstract
Medical records (2005-2009) of a feline-only practice were searched for cats with degenerative joint disease (DJD) treated using meloxicam. DJD was diagnosed by the presence of at least two of the following: (i) altered mobility (observed by the owner), (ii) abnormal physical findings, (iii) characteristic radiographic changes. The primary study cohort consisted of cats older than 7 years that had received meloxicam for variable intervals in excess of 6 months, and for which complete records were available. These cats were subdivided according to whether detectable chronic kidney disease (CKD) was present ('renal group'), or not ('non-renal group'), and, for the 'renal group', according to the cat's IRIS category. Serum biochemistry, urinalysis (including urine specific gravity [USG]), body mass and condition score were monitored regularly. Progression of CKD in the 'renal group' and 'non-renal group' of cats was compared to two groups of age- and IRIS-matched control cats not receiving meloxicam (from the same clinic, over the same time period). The study was thus a case-control design, with two study groups. Thirty-eight cats with DJD receiving long-term meloxicam therapy met the inclusion criteria. Of these, 22 cats had stable CKD at the start of treatment (stage 1, eight cats; stage 2, 13 cats; stage 3, one cat). No cats initially had an elevated urinary protein to creatinine ratio. The remaining 16 cats initially had normal renal analytes and adequately concentrated urine. The median age of the 'renal' and 'non-renal' meloxicam groups was 15.5 and 13.4 years, respectively. The median treatment duration was 467 days in the 'renal group' and 327 days in the 'non-renal group'. After titration (to the lowest effective dose), the median maintenance dose was 0.02 mg/kg/day in both groups (range 0.015-0.033 mg/kg/day). There was no difference in sequential serum creatinine concentration or USG measurements between the 'non-renal group' treated with meloxicam compared to control cats not treated with meloxicam. There was less progression of renal disease in the 'renal group' treated with meloxicam compared to the age- and IRIS-matched cats with CKD not given meloxicam. These results suggest that a long-term maintenance dose of 0.02 mg/kg of meloxicam can be safely administered to cats older than 7 years even if they have CKD, provided their overall clinical status is stable. Long-term meloxicam therapy may slow the progression of renal disease in some cats suffering from both CKD and DJD. Prospective studies are required to confirm these findings.
Collapse
|
16
|
Maddens B, Heiene R, Smets P, Svensson M, Aresu L, van der Lugt J, Daminet S, Meyer E. Evaluation of kidney injury in dogs with pyometra based on proteinuria, renal histomorphology, and urinary biomarkers. J Vet Intern Med 2011; 25:1075-83. [PMID: 21848947 DOI: 10.1111/j.1939-1676.2011.0772.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND Proteinuria is a feature of pyometra-associated renal dysfunction, but its prevalence and clinical relevance are not well characterized. OBJECTIVES To define which subset of dogs with pyometra has clinically relevant kidney injury by quantification of proteinuria; light, immunofluorescence, and electron microscopic examination of kidney biopsy specimens; and measurement of urinary biomarkers. ANIMALS Forty-seven dogs with pyometra. Ten clinically healthy intact bitches of comparable age. METHODS Prospective study. Routine clinicopathological variables including urinary protein to creatinine ratio (UPC) were analyzed. Validated assays were used to quantify urinary biomarkers for glomerular (urinary albumin, urinary immunoglobulin G, urinary C-reactive protein, urinary thromboxane B(2)) and tubular function (urinary retinol-binding protein, urinary N-acetyl-β-d-glucosaminidase). Kidney biopsy specimens from 10 dogs with pyometra and dipstick urine protein concentrations of 2+ or 3+ were collected during ovariohysterectomy. Urinalysis was repeated within 3 weeks after surgery in 9 of the 10 dogs. RESULTS UPC (median, range) was significantly higher in dogs with pyometra (0.48, 0.05-8.69) compared with healthy bitches (0.08, 0.02-0.16) (P < .01). Twenty-two of 47 dogs with pyometra had UPC>0.5, 12 had UPC>1.0, and 7 had UPC>2.0. Glomerulosclerosis and tubulointerstitial nephritis were common kidney biopsy findings in proteinuric dogs with pyometra. Dogs with glomerulosclerosis (5/10), either global or focal and segmental, had UPC>1.0 at ovariohysterectomy and afterward. Dogs with structural glomerular and tubular changes mostly had urinary biomarker to creatinine ratios above the 75th percentile. CONCLUSION Dogs with pyometra and UPC>1.0 or high ratios of urinary biomarkers appear likely to have clinically relevant renal histologic lesions and require monitoring after ovariohysterectomy. Future studies should evaluate the role of pyometra-associated pathogenic mechanisms in causing or exacerbating focal and segmental glomerulosclerosis in dogs.
Collapse
Affiliation(s)
- B Maddens
- Department of Pharmacology, Toxicology and Biochemistry, Ghent University, Merelbeke, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Muñoz A, Riber C, Trigo P, Castejón F. Clinical Applications of the Renin-Angiotensin-Aldosterone-Vasopressin Axis in the Horse and Future Directions for Research. J Equine Vet Sci 2010. [DOI: 10.1016/j.jevs.2010.10.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
18
|
Pittari J, Rodan I, Beekman G, Gunn-Moore D, Polzin D, Taboada J, Tuzio H, Zoran D. American association of feline practitioners. Senior care guidelines. J Feline Med Surg 2009; 11:763-78. [PMID: 19712895 PMCID: PMC11135487 DOI: 10.1016/j.jfms.2009.07.011] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Cats are the most popular pet in the United States and much of Northern Europe. Although 78% of owners consider their cats to be family members, many cats, particularly seniors, do not receive appropriate preventive care. One of the main obstacles to owner compliance is the lack of a clear recommendation by the veterinary team. Guidelines can help veterinarians to minimize this obstacle, strengthen the human-pet-veterinary bond, and improve the quality of life of cats. GOALS The goals of this article are to assist veterinarians to: Deliver consistent high-quality care to senior cats. Promote longevity and improve the quality of life of senior cats by: recognizing and controlling health risk factors; facilitating and promoting early detection of disease; improving or maintaining residual organ function; and delaying the progression of common conditions. Define aspects of screening, diagnosis, treatment and anesthesia of senior cats.
Collapse
|
19
|
Papich MG. An Update on Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Small Animals. Vet Clin North Am Small Anim Pract 2008; 38:1243-66, vi. [DOI: 10.1016/j.cvsm.2008.09.002] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
|
20
|
Mishina M, Watanabe T. Development of hypertension and effects of benazepril hydrochloride in a canine remnant kidney model of chronic renal failure. J Vet Med Sci 2008; 70:455-60. [PMID: 18525166 DOI: 10.1292/jvms.70.455] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
In order to determine whether hypertension would develop in dogs with chronic renal failure, we performed 7/8 renal ablation in 6 healthy dogs and compared pre- and post-ablation blood pressures determined by telemetry. One month after the renal ablation, blood urea nitrogen and creatinine were significantly increased (p<0.05), creatinine clearance was decreased (p<0.05), and blood pressure was increased significantly (p<0.05). Simultaneously, plasma renin activity, angiotensin I and II, and aldosterone were elevated significantly (p<0.05) compared with the values obtained from 11 healthy dogs with intact renal function. The dogs with induced renal failure and hypertension were administered an angiotensin-converting enzyme inhibitor, benazepril hydrochloride, once daily for 2 weeks at 2 mg/kg body weight, and changes in blood pressure and the renin-angiotensin-aldosterone (RAA) system were determined. During the administration of benazepril hydrochloride, blood pressure, angiotensin II and aldosterone decreased significantly (p<0.05) and, upon discontinuation of administration, increased to the pre-administration levels (p<0.05). Plasma renin activity and angiotensin I showed no significant changes throughout the administration study. These results provide experimental evidence that hypertension develops in dogs with chronic renal failure through mechanisms involving the RAA system and demonstrate that benazepril hydrochloride improves renal hypertension in dogs.
Collapse
Affiliation(s)
- Mika Mishina
- Department of Nephrology and Urology, Teaching Animal Hospital, Azabu University, Sagamihara, Kanagawa, Japan.
| | | |
Collapse
|
21
|
Desmoulins PO, Burgaud S, Horspool LJI. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats. J Vet Pharmacol Ther 2008; 31:349-58. [PMID: 18638296 DOI: 10.1111/j.1365-2885.2008.00959.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The pharmacokinetics of ramipril and its active metabolite, ramiprilat, was determined in cats following single and repeated oral doses of ramipril (Vasotop tablets) (once daily for 9 days) at dose rates of 0.125, 0.25, 0.5 and 1.0 mg/kg. The pharmacodynamic effects were assessed by measuring plasma angiotensin-converting enzyme (ACE) activity. Maximum ramipril concentrations were attained within 30 min following a single dose and declined rapidly (concentrations were below the limit of quantification 4 h after treatment). Peak ramiprilat concentrations were detected at approximately 1.5 h. The apparent terminal half-life (t((1/2)beta)) was > or =20 h irrespective of the dose. Ramiprilat accumulated in plasma (ratio of accumulation 1.3 to 1.9 depending on the dose rate) following repeated administration. Steady-state conditions were attained after the second dose. Excretion was predominant in faeces (87%) and to a lesser extent in urine (11%). The rate and extent of absorption of ramipril as well as its conversion to ramiprilat were not significantly influenced by the presence of food in the gastrointestinal tract. Plasma-ACE activity was almost completely abolished 0.5-2.0 h after treatment, irrespective of the dose rate. Significant inhibition of ACE activity of 54.7 to 82.6% (depending on the dosage) was still present 24 h after treatment. Treatment was well-tolerated in all cats. Ramipril at a dose rate of 0.125 mg/kg once daily produces significant and long-lasting inhibition of ACE activity in healthy cats. The appropriateness of this dosage regime needs to be confirmed in diseased cats.
Collapse
Affiliation(s)
- P O Desmoulins
- Intervet Pharma R&D, Angers Technopole, Rue Olivier de Serres, Beaucouzé Cedex, France
| | | | | |
Collapse
|
22
|
Chetboul V, Lefebvre HP, Sampedrano CC, Gouni V, Saponaro V, Serres F, Concordat D, Nicolle AP, Pouchelon JL. Comparative Adverse Cardiac Effects of Pimobendan and Benazepril Monotherapy in Dogs with Mild Degenerative Mitral Valve Disease: A Prospective, Controlled, Blinded, and Randomized Study. J Vet Intern Med 2007. [DOI: 10.1111/j.1939-1676.2007.tb03016.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
23
|
WATANABE T, MISHINA M. Effects of Benazepril Hydrochloride in Cats with Experimentally Induced or Spontaneously Occurring Chronic Renal Failure. J Vet Med Sci 2007; 69:1015-23. [DOI: 10.1292/jvms.69.1015] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Affiliation(s)
- Toshifumi WATANABE
- Department of Surgery, School of Veterinary Medicine, Azabu University
- Department of Nephrology and Urology, Teaching Animal Hospital, Azabu University
| | - Mika MISHINA
- Department of Nephrology and Urology, Teaching Animal Hospital, Azabu University
| |
Collapse
|
24
|
Daull P, Lepage R, Benrezzak O, Cayer J, Beaudoin M, Belleville K, Blouin A, Sirois P, Nantel F, Jeng AY, Battistini B. The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats. Drug Chem Toxicol 2006; 29:183-202. [PMID: 16707327 DOI: 10.1080/01480540600566717] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
CGS 35601 is a triple vasopeptidase inhibitor (VPI) of angiotensin-converting enzyme, neutral endopeptidase, and endothelin-converting enzyme-1 with respective IC50 values of 22, 2, and 55 nM. We characterized the safety profile and toxicity of escalating doses of CGS 35601 over a 20-day period in chronically instrumented, unrestrained, conscious, male, spontaneously hypertensive rats (SHR). Once instrumented with an arterial catheter, the SHR were placed in metabolic cages allowing daily assessment of hemodynamics and blood sampling for biochemical and hematological measurements. After a 7-day stabilization period, the SHR were divided into 2 groups: Gr. 1, (n = 13 to 18) receiving CGS 35601 at 0.01, 0.1, 1 and 5 mg kg(-1) day(-1) (continuous i.a. infusion) for 5 consecutive days/dose, followed by a 5-day washout; and Gr. 2, (n = 10) receiving vehicle (saline). The highest dose of CGS 35601 dose-dependently reduced MABP from 156 +/- 4 up to 94 +/- 5 mm Hg, whereas heart rate, metabolic, electrolytic, and hematological profiles, growth, diuresis, and renal activity were unaffected, and no hepatic or liver toxicities were observed. These results suggest that this novel triple VPI presents no safety concerns at this stage and may become of interest for the treatment of hypertension and other cardiovascular disorders. Long-term chronic experiments are needed to assess possible angioedema and increases in vascular permeability.
Collapse
Affiliation(s)
- P Daull
- Department of Medicine, Laval University, Laval Hospital Research Center, Quebec Heart and Lung Institute, Ste-Foy, QC, Canada
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Lefebvre HP, Jeunesse E, Laroute V, Toutain PL. Pharmacokinetic and Pharmacodynamic Parameters of Ramipril and Ramiprilat in Healthy Dogs and Dogs with Reduced Glomerular Filtration Rate. J Vet Intern Med 2006. [DOI: 10.1111/j.1939-1676.2006.tb02888.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|